Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

EUMelaReg study published in European Journal of Cancer (EJC)

We are delighted to inform that the EUMelaReg study "Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study" was published at the European Journal of Cancer (EJC).

The background if the study is that adjuvant immune checkpoint inhibition (ICI) with anti-PD-1 antibodies in high-risk resected melanoma has been shown to improve recurrence-free survival. It is unclear whether prior adjuvant anti-PD-1 therapy is associated with altered response to subsequent ICI treatment in the metastatic setting.

Examined were data from the European Melanoma Registry (EUMelaReg) were used to assess the efficacy of first-line ICI in unresectable or metastatic melanoma following prior adjuvant anti-PD-1 therapy. Both anti-PD-1 monotherapy and Ipi/Nivo combination were analyzed. A total of 389 pretreated patients were matched 1:1 with 3390 PD-1–naive cases based on treatment type and prognostic factors. Outcomes included overall response rate (ORR) and progression-free survival (PFS), evaluated using Kaplan-Meier and Cox regression analysis.

Main results of the study is that out of 389 patients, 303 received Ipi/Nivo and 86 anti-PD-1 in 1L. ORR was lower in pre-treated patients (31.4%) vs. anti-PD-1-naive (48.8%; p < 0.0001). Median PFS was shorter in pre-treated patients for both therapies. Early recurrence after adjuvant therapy led to lower ORR (28.5%) and shorter PFS (3.1 months) than later recurrence (37.7%, 6.1 months).

The conclusion of the study is that patients with metastatic melanoma, previously exposed to anti-PD-1 ICI in the adjuvant setting showed significantly lower ORR and shorter PFS to 1L ICI with either Ipi/Nivo or single-agent anti-PD-1 retreatment.

All details of this study can be found here.